Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at Barclays PLC from $150.00 to $160.00. They now have an "overweight" rating on the stock.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at Royal Bank of Canada from $141.00 to $143.00. They now have an "outperform" rating on the stock.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its "buy" rating re-affirmed by analysts at HC Wainwright.
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance [Yahoo! Finance]
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance